Renal Biomarkers Market - 47% of Growth to Originate from North America| Evolving Opportunities with Abbott Laboratories & bioMerieux SA |17000+ Technavio Reports
NEW YORK , March 22, 2022 /PRNewswire/ -- The "Renal Biomarkers Market - Competitive Analysis, Drivers, Trends, Challenges and Five Force Analysis" report has been added to Technavio's offering. The renal biomarkers market is estimated to grow by USD 507.23 million from 2021 to 2026. However, the growth momentum is likely to decelerate at a CAGR of 7.40%. 47% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for renal biomarkers market in North America. Market growth in this region will be faster than the growth of the market in ROW. The increasing number of support programs conducted by vendors and various organizations will facilitate the renal biomarkers market growth in North America over the forecast period.
For more insights on the market share of various regions - Download a free sample now!
Renal Biomarkers Market Dynamics
Factors such as the rising prevalence of chronic kidney diseases, increase in the incidence of acute kidney injury and associated risk factors, and the rapid increase in the aging population will drive the growth of the Renal Biomarkers Market. However, limitations and complications involved in renal biomarkers might hamper the market growth. The holistic analysis of the drivers, trends & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Renal Biomarkers Market: Company Profiles
The renal biomarkers market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market. The renal biomarkers market report includes information on the product launches, sustainability, and prospects of leading vendors including Abbott Laboratories, bioMerieux SA, BioPorto AS, F. Hoffmann-La Roche Ltd., IQVIA Holdings Inc., Randox Laboratories Ltd., RenalSense Ltd., Siemens AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc..
Few companies with their key offerings
- Abbott Laboratories - The company provides renal biomarkers for the diagnosis and management of patients with acute kidney injury and chronic kidney disease.
- bioMerieux SA - The company offers renal biomarkers such as Nephrocheck system - TIMP-2 and IGFBP-7.
- BioPorto AS - The company offers renal biomarkers such as NGAL Biomarker which is fast, additive, and prognostic
- F. Hoffmann-La Roche Ltd. - The company provides renal biomarkers such as Tina-quant Cystatin C.
- IQVIA Holdings Inc. - The company offers renal biomarkers such as KidneyMAP panels, which detect early signs of renal damage which is a common problem in drug development programs.
- To know about all major vendors with their key offerings - Download a free sample now!
Renal Biomarkers Market: Competitive Analysis
The competitive scenario provided in the renal biomarkers market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
Renal Biomarkers Market: Segmentation Analysis
- By End-user, the market is classified as hospitals, clinics, diagnostic laboratories, and research laboratories.
- By Geography, the market is classified as North America, Europe, Asia, and ROW.
For additional information on the contribution of each segment - Download a free sample now!
Related Reports
- The animal biotechnology market share is expected to increase by USD 3.26 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 2.82%. Download a free sample now!
- The orthobiologics market has the potential to grow by USD 2.02 bn during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 7.01%. Download a free sample now!
Renal Biomarkers Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2021 |
Forecast period | 2022-2026 |
Growth momentum & CAGR | Decelerate at a CAGR of 7.40% |
Market growth 2022-2026 | USD 507.23 million |
Market structure | Concentrated |
YoY growth (%) | 9.97 |
Performing market contribution | North America at 47% |
Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
Companies profiled | Abbott Laboratories, bioMerieux SA, BioPorto AS, F. Hoffmann-La Roche Ltd., IQVIA Holdings Inc., Randox Laboratories Ltd., RenalSense Ltd., Siemens AG, SphingoTec GmbH, and Thermo Fisher Scientific Inc. |
Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Content
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
Exhibit 08: Parent market
Exhibit 09: Market characteristics
2.2 Value chain analysis
Exhibit 10: Value chain analysis:Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.3 Manufacturing
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support services
2.2.7 Innovation
3. Market Sizing
3.1 Market segment analysis
Exhibit 11: Market segments
3.2 Market size 2021
3.3 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.4 Market outlook: Forecast for 2021 - 2026
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5 Market Segmentation by End-user
5.1 Market segments
Exhibit 22: End-user - Market share 2021-2026 (%)
5.2 Comparison by End-user
Exhibit 23: Comparison by End-user
5.3 Hospitals - Market size and forecast 2021-2026
Exhibit 24: Hospitals - Market size and forecast 2021-2026 ($ million)
Exhibit 25: Hospitals - Year-over-year growth 2021-2026 (%)
5.4 Clinics and diagnostic laboratories - Market size and forecast 2021-2026
Exhibit 26: Clinics and diagnostic laboratories - Market size and forecast 2021-2026 ($ million)
Exhibit 27: Clinics and diagnostic laboratories - Year-over-year growth 2021-2026 (%)
5.5 Research laboratories - Market size and forecast 2021-2026
Exhibit 28: Research laboratories - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Research laboratories - Year-over-year growth 2021-2026 (%)
5.6 Market opportunity by End-user
Exhibit 30: Market opportunity by End-user
6. Customer landscape
6.1 Overview
Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 31: Customer landscape?
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 32: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 33: Geographic comparison
7.3 North America - Market size and forecast 2020-2025
Exhibit 34: North America - Market size and forecast 2020-2025 ($ million)
Exhibit 35: North America - Year-over-year growth 2020-2025 (%)
7.4 Europe - Market size and forecast 2020-2025
Exhibit 36: Europe - Market size and forecast 2020-2025 ($ million)
Exhibit 37: Europe - Year-over-year growth 2020-2025 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 38: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 39: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2020-2025
Exhibit 40: ROW - Market size and forecast 2020-2025 ($ million)
Exhibit 41: ROW - Year-over-year growth 2020-2025 (%)
7.7 Key leading countries
Exhibit 42: Key leading countries
7.8 Market opportunity by geography
Exhibit 43: Market opportunity by geography
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Rising prevalence of chronic kidney diseases
8.1.2 Increase in incidence of acute kidney injury (AKI) and associated risk factors
8.1.3 Rapid increase in the aging population
8.2 Market challenges
8.2.1 Limitations of and complications involved in renal biomarkers
8.2.2 Stringent regulatory guidelines
8.2.3 High cost of treatment
Exhibit 44: Impact of drivers and challenges
8.3 Market trends
8.3.1 Increasing awareness about kidney diseases
8.3.2 Opportunities in emerging markets
8.3.3 Focus on miniaturization and wearable technology and that for infant and pediatric applications
9. Vendor Landscape
9.1 Overview
Exhibit 45: Vendor landscape
The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
9.2 Landscape disruption
Exhibit 46: ?Landscape disruption?
Exhibit 47: Industry risks
9.3 Competitive Scenario
10. Vendor Analysis
10.1 Vendors covered
Exhibit 48: Vendors covered
10.2 Market positioning of vendors
Exhibit 49: ?Market positioning of vendors?
10.3 Abbott Laboratories
Exhibit 50: Abbott Laboratories - Overview
Exhibit 51: Abbott Laboratories - Business segments
Exhibit 52: Abbott Laboratories - Key news
Exhibit 53: Abbott Laboratories - Key offerings
Exhibit 54: Abbott Laboratories - Segment focus
10.4 bioMerieux SA
Exhibit 55: bioMerieux SA - Overview
Exhibit 56: bioMerieux SA - Business segments
Exhibit 57: bioMerieux SA - Key news
Exhibit 58: bioMerieux SA - Key offerings
Exhibit 59: bioMerieux SA - Segment focus
10.5 BioPorto AS
Exhibit 60: BioPorto AS - Overview
Exhibit 61: BioPorto AS - Product and service
Exhibit 62: BioPorto AS - Key offerings
10.6 F. Hoffmann-La Roche Ltd.
Exhibit 63: F. Hoffmann-La Roche Ltd. - Overview
Exhibit 64: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 65: F. Hoffmann-La Roche Ltd. - Key news
Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. - Segment focus
10.7 IQVIA Holdings Inc.
Exhibit 68: IQVIA Holdings Inc. - Overview
Exhibit 69: IQVIA Holdings Inc. - Business segments
Exhibit 70: IQVIA Holdings Inc. - Key offerings
Exhibit 71: IQVIA Holdings Inc. - Segment focus
10.8 Randox Laboratories Ltd.
Exhibit 72: Randox Laboratories Ltd. - Overview
Exhibit 73: Randox Laboratories Ltd. - Product and service
Exhibit 74: Randox Laboratories Ltd. - Key offerings
10.9 RenalSense Ltd.
Exhibit 75: RenalSense Ltd. - Overview
Exhibit 76: RenalSense Ltd. - Product and service
Exhibit 77: RenalSense Ltd. - Key offerings
10.10 Siemens AG
Exhibit 78: Siemens AG - Overview
Exhibit 79: Siemens AG - Business segments
Exhibit 80: Siemens AG - Key offerings
Exhibit 81: Siemens AG - Segment focus
10.11 SphingoTec GmbH
Exhibit 82: SphingoTec GmbH - Overview
Exhibit 83: SphingoTec GmbH - Product and service
Exhibit 84: SphingoTec GmbH - Key news
Exhibit 85: SphingoTec GmbH - Key offerings
10.12 Thermo Fisher Scientific Inc.
Exhibit 86: Thermo Fisher Scientific Inc. - Overview
Exhibit 87: Thermo Fisher Scientific Inc. - Business segments
Exhibit 88: Thermo Fisher Scientific Inc. - Key news
Exhibit 89: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 90: Thermo Fisher Scientific Inc. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2Objectives
11.1.3 Notes and Caveats
11.2 Currency conversion rates for US$
Exhibit 91:Currency conversion rates for US$?
11.3 Research Methodology
Exhibit 92: Research Methodology
Exhibit 93: Validation techniques employed for market sizing?
Exhibit 94: Information sources
11.4 List of abbreviations
Exhibit 95: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article